THE INVESTOR

▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald

Bio

November 20, 2024
Samsung Biologics hits W5tr in annual orders

Samsung Biologics said Wednesday that its cumulative orders this year have exceeded 5 trillion won ($3.59 billion), driven by consecutive large-scale deals with global pharmaceutical companies. In a regulatory filing, the company announced two new contract manufacturing agreements with a European ...
November 19, 2024
Daewoong develops drug candidate for oral obesity treatment

Daewoong Pharmaceutical announced Tuesday that it has filed for a domestic patent for a new obesity drug that suppresses appetite and promotes fat burning. The company said the candidate drug targets both GLP-1 and GIP receptors and is designed as a small molecule-based oral agonist. GLP-1 and GIP...
November 08, 2024
Celltrion hits record Q3 sales

South Korean biopharmaceutical company Celltrion said Friday it achieved record revenue in the third quarter, driven largely by increased global prescriptions of its flagship biosimilar products. According to a regulatory filing, Celltrion posted consolidated sales of 881.9 billion won ($645.7 mil...
November 06, 2024
Miracell showcases stem cell tech at Spain conference

South Korean stem cell research company Miracell showcased its stem cell extraction system, Smart M-Cell, during the IV Congreso Semdor Valencia conference in Spain last month. Hosted by the Spanish Pain Society, the annual conference brought together pain management experts from around the world ...
November 04, 2024
Celltrion expands European reach with anti-imflammatory drug

Celltrion has launched Steqeyma, a biosimilar of Stelara (ustekinumab) for autoimmune disease treatment, across Europe, broadening its product portfolio to further strengthen its position in the European biopharmaceutical market. On Friday, Celltrion introduced Steqeyma in Germany, one of Europe’...
October 29, 2024
Celltrion's Zymfentra secures more insurance coverage in US

Celltrion has secured contracts to list its Zymfentra — the world’s only subcutaneous injection formulation of its infliximab Remsima — across all public and private insurance sectors managed by the top three US pharmacy benefit managers. Celltrion announced Tuesday that it had recently finaliz...
October 23, 2024
SK’s flu vaccine spreading across Asia

South Korean pharmaceutical company SK Bioscience said Wednesday that its SKYCellflu has become the first influenza vaccine from Korea approved by the Food and Drug Agency of Indonesia. Indonesia’s pharmaceutical market has been growing significantly. According to market tracker Insights10, the c...
October 17, 2024
LG Chem to develop plant-based cosmetics ingredient

LG Chem said Thursday that it plans to commercialize an eco-friendly ingredient derived from plant-based oils for cosmetic products, becoming the first to do so. The South Korean chemicals giant is set to develop functional cosmetics using 100 percent bio-based 3-hydroxypropionic acid, a compound ...
October 14, 2024
Samsung Biologics unveils new platform

Samsung Biologics announced Monday that it has launched S-HiCon, a new platform specializing in high-concentration formulation development, designed to meet rising demand for high-concentration biopharmaceuticals. The company officially introduced the platform at Bio Japan 2024, a biotechnology ex...
October 08, 2024
SK Bioscience acquires $3m stake in US biotech firm

South Korean biotech firm SK Bioscience said Tuesday it has invested $3 million in the US-based biotech firm Fina Biosolutions to acquire a stake in the company as part of the company’s broader strategy to secure next-generation vaccine technologies and enhance its global competitiveness in the va...
October 02, 2024
SK Innovation develops low-cost membrane for carbon capture

SK Innovation, with its subsidiary SK IE Technology and researchers from Yonsei University, has developed a next-generation technology designed to capture carbon emissions more efficiently and at a lower cost. This breakthrough could have significant implications for the biggest carbon-emitting ind...
September 30, 2024
Daewoong's new drug patents reach 88% of total

South Korean drug maker Daewoong Pharmaceutical said Monday that more than 88 percent of its patents registered over the past five years in the country have been for new drugs, reflecting the firm’s efforts to enhance its competitiveness in both domestic and global markets through the development ...
September 20, 2024
Yuhan, Janssen halt next-gen cancer drug collaboration

South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the development of a next-generation targeted anticancer drug, citing the strong efficacy of its existing treatment, which has reduced the need for further development. According to...
September 19, 2024
Daewoong to lead homegrown hyperlipidemia therapy

According to the group, most raw materials for hyperlipidemia drugs produced in Korea are currently manufactured using a "batch process" method, which operates each process separately. In contrast, Daewoong's "continuous process" ensures consistent quality by allowing raw materials to be input in a...
September 13, 2024
Celltrion secures contract to supply Herzuma to Brazil for 5th year

South Korean biosimilar giant Celltrion will continue to supply trastuzumab biosimilar Herzuma to Brazil, the company announced Friday. The company won the bid to supply a trastuzumab biosimilar to the Brazilian Federal Government for the fifth consecutive year. Under the contract, Celltrion will...

1 2 3 4 5 6

EDITOR'S PICKS

Herald Corporation |CEO : Choi Jin-Young |Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea |Title : The Investor |Date of registration : 2016.06.21 |Date of issue : 2016.06.21
Publisher. Editor : Choi Jin-Young |Chief Privacy Officer & Juvenile Protection Manager : Choi He-suk |T +82-2-727-0021 |E investor@heraldcorp.com

FAMILY SITE GO

Company Registration No. 104-81-06004 |Mail-Order Business Registration 2016 - Seoul Yongsan - 00590 |Business info |Gov’t registration No. Seoul 아04099